TRAWS PHARMA ($TRAW) posted quarterly earnings results on Monday, March 31st. The company reported earnings of $95.66 per share, beating estimates of -$9.74 by $105.40. The company also reported revenue of $60,000, missing estimates of $61,200 by $-1,200.
You can see Quiver Quantitative's $TRAW stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TRAWS PHARMA Hedge Fund Activity
We have seen 0 institutional investors add shares of TRAWS PHARMA stock to their portfolio, and 26 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORBIMED ADVISORS LLC removed 1,045,261 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $6,146,134
- VANGUARD GROUP INC removed 706,921 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $4,156,695
- BLACKROCK, INC. removed 248,878 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,463,402
- GEODE CAPITAL MANAGEMENT, LLC removed 224,086 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,317,625
- RENAISSANCE TECHNOLOGIES LLC removed 218,094 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,282,392
- CITADEL ADVISORS LLC removed 121,011 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $711,544
- UBS GROUP AG removed 98,578 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $579,638
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
